1. Home
  2. JYNT vs NKTX Comparison

JYNT vs NKTX Comparison

Compare JYNT & NKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo The Joint Corp.

JYNT

The Joint Corp.

HOLD

Current Price

$9.74

Market Cap

145.4M

Sector

Miscellaneous

ML Signal

HOLD

Logo Nkarta Inc.

NKTX

Nkarta Inc.

HOLD

Current Price

$2.01

Market Cap

132.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
JYNT
NKTX
Founded
2010
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Multi-Sector Companies
Biotechnology: Pharmaceutical Preparations
Sector
Miscellaneous
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
145.4M
132.8M
IPO Year
2014
2020

Fundamental Metrics

Financial Performance
Metric
JYNT
NKTX
Price
$9.74
$2.01
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
5
Target Price
$17.00
$13.25
AVG Volume (30 Days)
56.3K
873.9K
Earning Date
03-12-2026
03-25-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$54,176,002.00
N/A
Revenue This Year
$5.65
N/A
Revenue Next Year
$3.86
N/A
P/E Ratio
N/A
N/A
Revenue Growth
10.47
N/A
52 Week Low
$7.50
$1.31
52 Week High
$13.47
$2.74

Technical Indicators

Market Signals
Indicator
JYNT
NKTX
Relative Strength Index (RSI) 52.52 42.66
Support Level $9.37 $1.91
Resistance Level $10.22 $2.27
Average True Range (ATR) 0.37 0.14
MACD -0.06 -0.05
Stochastic Oscillator 38.42 8.70

Price Performance

Historical Comparison
JYNT
NKTX

About JYNT The Joint Corp.

The Joint Corp develops, owns, operates, supports, and manages chiropractic clinics through direct ownership, management arrangements, franchising, and the sales of regional developer rights throughout the United States. The doctors of chiropractic develop personalized treatment plans to relieve patients' pain and deliver ongoing preventative care. The Company has one operating business segment; The Franchise Operations segment which is comprised of the operating activities of the franchise business unit. The Franchise Operations segment derives revenue from customers by providing access to the Company's franchise license, which represents symbolic intellectual property.

About NKTX Nkarta Inc.

Nkarta Inc is a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The Company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of therapeutic targets, and improve persistence for sustained activity in the body for the treatment of cancer.

Share on Social Networks: